title: Regulating autologous adult stem cells: the FDA steps up.
abstract: The Food and Drug Administration (FDA) has sought an injunction to prevent a US-based company from offering an autologous adult stem cell treatment for musculoskeletal and spinal injuries. Given the alarming number of clinics promoting stem-cell-based interventions, the outcome of this case could have wide-ranging implications.
authors: Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228. tamra.lysaght@nuhs.edu.sg
authors: Tamra
authors: T
authors: Lysaght
authors: Alastair V
authors: AV
authors: Campbell
mesh_terms: D000328:Adult; D053687:Adult Stem Cells / Q000166:cytology*; D006801:Humans; D011057:Politics; D044968:Regenerative Medicine / Q000331:legislation & jurisprudence; D014182:Transplantation, Autologous; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*